Q1 EPS Forecast for Vanda Pharmaceuticals Reduced by Analyst

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – HC Wainwright cut their Q1 2026 EPS estimates for shares of Vanda Pharmaceuticals in a research report issued on Tuesday, February 17th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings per share of ($0.57) for the quarter, down from their previous estimate of ($0.24). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.65) EPS and FY2027 earnings at ($0.54) EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.18) by ($0.21). The firm had revenue of $57.22 million during the quarter, compared to analysts’ expectations of $59.28 million. Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.

VNDA has been the topic of a number of other research reports. Jefferies Financial Group increased their target price on Vanda Pharmaceuticals from $5.00 to $7.50 and gave the stock a “hold” rating in a research note on Wednesday, December 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, January 21st. Zacks Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 11th. B. Riley Financial raised their target price on shares of Vanda Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, December 31st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $13.63.

Vanda Pharmaceuticals Price Performance

Shares of VNDA stock opened at $6.10 on Thursday. The stock has a 50 day moving average price of $7.33 and a 200 day moving average price of $5.73. Vanda Pharmaceuticals has a 52-week low of $3.81 and a 52-week high of $9.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.38 and a current ratio of 2.39. The firm has a market capitalization of $360.57 million, a P/E ratio of -1.64 and a beta of 0.62.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of VNDA. Torren Management LLC purchased a new position in Vanda Pharmaceuticals during the fourth quarter valued at approximately $25,000. Russell Investments Group Ltd. boosted its position in Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 5,328 shares in the last quarter. CWM LLC grew its holdings in Vanda Pharmaceuticals by 424.6% in the second quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 7,575 shares during the period. Quarry LP purchased a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at approximately $53,000. Finally, Cerity Partners LLC acquired a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth approximately $69,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

More Vanda Pharmaceuticals News

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Bullish analyst commentary and upside math: TipRanks highlights strong upside (reporting ~126% potential) tied to the upcoming FDA decision on Bysanti, which is driving speculative buying ahead of the PDUFA. FDA Calendar: Vanda Stock (VNDA) Shows 126% Upside with Bysanti Decision on Deck
• Positive Sentiment: Brokerage consensus leans supportive: Coverage summary cites a “Moderate Buy” consensus from brokerages, which can sustain buying interest into the FDA event. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: Heavy media and retail buzz: Coverage notes pronounced market chatter and increased attention ahead of the FDA verdict — this fuels volume and volatility but not a directional guarantee. Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti for bipolar, schizophrenia
• Neutral Sentiment: High risk / discounted framing: A Seeking Alpha piece flags VNDA as high‑risk but possibly undervalued ahead of PDUFA — reinforcing a binary outcome: big upside if approval/positive labeling, big downside if not. Vanda Pharma: High Risk, Heavily Discounted – Stock Ahead Of PDUFA This Week
• Negative Sentiment: HC Wainwright cut near‑term earnings forecasts materially: The analyst reduced Q1–Q4 2026 and FY2026 EPS estimates (FY2026 now seen at about ($1.65)), signaling weaker near‑term financials and higher cash burn expectations even while maintaining a “Buy” rating and $22 target — this raises execution risk if clinical/commercial progress or cash needs diverge. (Source: HC Wainwright research note)

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.